General Information:

Id: 1,441
Diseases: Alzheimer disease - [OMIM]
Hemochromatosis, type 1 - [OMIM]
Mammalia
review
Reference: Cahill CM et al.(2009) Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases Biochim. Biophys. Acta 1790: 615-628 [PMID: 19166904]

Interaction Information:

Comment There are evidences of metal dependent translation of APP mRNA, the involvement of metals in the plaque of AD patients and of increased iron in striatal neurons in the substantia nigra (SN) of Parkinson's disease patients.
Formal Description
Interaction-ID: 10118

drug/chemical compound

Metal

affects_expression of

gene/protein

APP

Drugbank entries Show/Hide entries for APP
Comment There are evidences of metal dependent translation of APP mRNA, the involvement of metals in the plaque of AD patients and of increased iron in striatal neurons in the substantia nigra (SN) of Parkinson's disease patients.
Formal Description
Interaction-ID: 10317

drug/chemical compound

Metal

affects_quantity of

phenotype

amyloid beta deposits

Comment There are evidences of metal dependent translation of APP mRNA, the involvement of metals in the plaque of AD patients and of increased iron in striatal neurons in the substantia nigra (SN) of Parkinson's disease patients.
Formal Description
Interaction-ID: 10318

drug/chemical compound

Iron

affects_activity of

tissue/cell line

striatal neuron

in the substantia nigra (SN); of Parkinson's disease patients
Comment Individuals homozygous for the E4 allele of apolipoprotein E (ApoE) are at increased risk for developing Alzheimer's disease.
Formal Description
Interaction-ID: 10320

gene/protein mutant

APOE (isoform E4)

increases_activity of

disease

Alzheimer disease

Comment There are evidences of metal dependent translation of APP mRNA, the involvement of metals in the plaque of AD patients and of increased iron in striatal neurons in the substantia nigra (SN) of Parkinson's disease patients.
Formal Description
Interaction-ID: 10321

disease

Alzheimer disease

increases_quantity of

phenotype

amyloid beta deposits

Comment Genetic studies demonstrated the involvement of the transferrin C2 allele to increase risk of Alzheimer's disease.
Formal Description
Interaction-ID: 10322

gene/protein mutant

TF C2-mut

increases_activity of

disease

Alzheimer disease

Comment Genetic studies demonstrated the clear involvement of the genotype of the HFE gene in hemochromatosis (iron overload) to increase risk of Alzheimer's disease.
Formal Description
Interaction-ID: 10346

gene/protein

HFE

affects_activity of

disease

Alzheimer disease

Comment Genetic studies demonstrated the clear involvement of the genotype of the HFE gene in hemochromatosis (iron overload) to increase risk of Alzheimer's disease.
Formal Description
Interaction-ID: 10347

gene/protein

HFE

affects_activity of

disease

Hemochromatosis, type 1

Comment Patients carrying the mutant HFE-H63D allele had a mean age of AD onset at 71.7+/-6.0 years versus 76.6+/-5.8 years of those who were homozygous for the wild-type allele.
Formal Description
Interaction-ID: 10348

gene/protein mutant

HFE-p.H63D

increases_activity of

disease

Alzheimer disease

Comment Iron is a risk factor for late onset Alzheimer's disease. Excess iron accumulation is a consistent observation in the AD brain.
Formal Description
Interaction-ID: 10349

phenotype

abnormal iron level

increases_activity of

disease

Alzheimer disease

Comment Brain autopsy samples from AD patients have elevated levels of ferritin iron, particularly in the neurons of the basal ganglia and most amyloid plaques contain iron and ferritin-rich cells.
Formal Description
Interaction-ID: 10350

drug/chemical compound

Iron

is localized in

tissue/cell line

basal ganglion

in AD patients
Comment Brain autopsy samples from AD patients have elevated levels of ferritin iron, particularly in the neurons of the basal ganglia and most amyloid plaques contain iron and ferritin-rich cells.
Formal Description
Interaction-ID: 10351

drug/chemical compound

Iron

is localized in

phenotype

ferritin-rich cell

in AD patients
Comment Clinically there is a reported decrease in the rate of decline in AD patients who were treated with the intramuscular iron chelator, desferrioxamine.
Formal Description
Interaction-ID: 10352

drug/chemical compound

Desferrioxamine

decreases_activity of

disease

Alzheimer disease

Comment Iron enhances cleavage of the Abeta-peptide domain of APP by the metalloprotease alpha secretase.
Formal Description
Interaction-ID: 10384

drug/chemical compound

Iron

increases_activity of

gene/protein

Alpha-secretase

Comment Iron enhances cleavage of the Abeta-peptide domain of APP by the metalloprotease alpha secretase.
Formal Description
Interaction-ID: 10385

gene/protein

Alpha-secretase

increases_processing of

gene/protein

APP

Drugbank entries Show/Hide entries for APP
Comment APP transcription is up-regulated by copper.
Formal Description
Interaction-ID: 10386

drug/chemical compound

Copper

increases_expression of

gene/protein

APP

Up-regulation of APP transcription
Drugbank entries Show/Hide entries for APP